Dataset from A Randomized, Double-blind, Multicenter, Active-Controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression

The purpose of this study is to assess the efficacy of intranasal esketamine plus an oral
antidepressant compared with an oral antidepressant (active comparator) plus intranasal
placebo in delaying relapse of depressive symptoms in participants with treatment-resistant
depression (TRD) who are in stable remission after an induction and optimization course of
intranasal esketamine plus an oral antidepressant.